血脂康对高脂血症患者小而密低密度脂蛋白的影响

目的:观察血脂康对高脂血症患者血浆小而密低密度脂蛋白(sLDL)的影响。方法:以50例高脂血症患者为治疗组,20例正常健康人为正常对照组。治疗组病人每日口服1.2g血脂康,共服6周。服药前后常规测定血脂。2%～16%非变性梯度凝胶电泳法分离出sLDL,扫描仪半定量分析sLDL的含量,并计算sLDL中的胆固醇(sLDL-C)含量。结果:治疗组服用血脂康后血清TC、低密度脂蛋白-胆固醇(LDL-C)、TG显著降低(P<0.01);治疗组调脂治疗前sLDL占低密度脂蛋白(LDL)的相对值及sLDL-C含量明显高于正常对照组。调脂治疗6周后,治疗组sLDL占LDL的相对值及sLDL-C的实际含量显著下降,分别为44±12vs39±10、1.65±0.31vs1.03±0.21,均为P<0.05。结论:血脂康在调节血脂水平的同时可有效降低sLDL及sLDL-C的含量。

Effect of Xuezhikang on LDL subfractions in hyperlipemia patients

AIM: To investigate the effect of Xuezhikang on blood plasm LDL subfractio in hyperlipemia patients and to assess effects of lipid-lowering therapy of Xuezhikang. METHODS: 50 hyperlipemia patients as treatment group, and 20 normal persons as control group took part in the experiments. The patients took 1.2 g Xuezhikang orally everyday for 6 weeks. The serum TC,TG and H-C of patients and normal control were detected by enzyme methods; LDL subfraction were separated by 2%-16% non-denaturing polyacryamide gel electrophoresis. The LDL subfractions distributions were analyzed by the measurement of the area under the band of the scanned gel. Various indexes were measured before and after lipid-lowering therapy, and were contrasted with those in control group. RESULTS: Compared with that in control group the small dense LDL(sLDL) in treatment group was obviously elevated. After lipid-lowering therapy, the levels of sLDL were obviously decreased(P<0.05). CONCLUSION:Xuezhikang of lipid-lowering therapy can decrease the distribution levels of sLDL and sLDL-C.